Prognostic factors for cancer treatment

摘要

1. A method for predicting the response of an oncological patient to anticancer therapy, comprising determining the level or amount of a first prognostic factor in a biological sample of said patient, said first prognostic factor being CD68 or PSMB1 polymorphism (P11A); and determining the presence or amount of a second prognostic factor in said patient; moreover, low CD68 or the presence of PSMB1 (P11A) polymorphism correlates with at least one positive outcome, and the presence, absence or amount of said second prognostic factor correlates with at least one positive outcome. The method of claim 1, wherein the first prognostic factor is a low level of CD68.3. A method according to claim 2, wherein the low level of CD68 is 50% or less of CD68-positive cells according to the results of immunohistochemical analysis. The method of claim 1, wherein the first prognostic factor is PSMB1 (P11A) polymorphism. The method of claim 1, wherein the second prognostic factor is selected from the group consisting of: low CD68, polymorphism PSMB1 (P11A), polymorphism PSMB5 (R24C), age under 65, one previous treatment, low International prognostic index for follicular lymphomas (FLIPI) and low tumor burden. 6. The method of claim 1, wherein the cancer is hemoblastosis. The method of claim 6, wherein the hemoblastosis is follicular B-cell non-Hodgkin lymphoma or multiple myeloma. The method of claim 1, wherein said treatment comprises treatment with a proteosome inhibitor. The method of claim 9, wherein said �